Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
7
Neutral
3
Bullish
4
Bearish
16
Neutral
3
Bullish
27
Bearish
9
Neutral
0
Bullish
23
Discovery themes featuring this stock
Trident Lifeline Limited is a rapidly growing pharmaceutical company, specializing in manufacturing and exporting pharmaceutical formulations globally. It operates in several regions, including Africa, Latin America, and Asia.
The company has shown robust financial growth, with a 44% year-over-year revenue increase in Q3FY26. Its EBITDA also surged by 53% in the same period, demonstrating a strong operational performance.
Strategic acquisitions have been pivotal for Trident, acquiring stakes in subsidiaries like TNS Pharma, TLL Parenterals, and Trident Mediquip, enhancing its manufacturing and distribution capabilities.
A hybrid manufacturing model is at the core of Trident's operations, combining in-house manufacturing with contract manufacturing to meet growing demands effectively.
Trident Lifeline is heavily investing in product registrations, with over 3,500 products in the pipeline, which could significantly propel its market presence and revenue growth in the coming years.
Pharmaceuticals & Biotechnology
Pharmaceuticals
324 Cr
Low Risk
17.0
34.3
0.3
3.2
328.00
229.95
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Trident Lifeline Ltd (TLL) is currently trading at 269.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Trident Lifeline Limited is a rapidly growing pharmaceutical company, specializing in manufacturing and exporting pharmaceutical formulations globally. It operates in several regions, including Africa, Latin America, and Asia. The company has shown robust financial growth, with a 44% year-over-year revenue increase in Q3FY26. Its EBITDA also surged by 53% in the same period, demonstrating a strong operational performance. Strategic acquisitions have been pivotal for Trident, acquiring stakes in subsidiaries like TNS Pharma, TLL Parenterals, and Trident Mediquip, enhancing its manufacturing and distribution capabilities. A hybrid manufacturing model is at the core of Trident's operations, combining in-house manufacturing with contract manufacturing to meet growing demands effectively. Trident Lifeline is heavily investing in product registrations, with over 3,500 products in the pipeline, which could significantly propel its market presence and revenue growth in the coming years.
Over the past 52 weeks, Trident Lifeline Ltd has traded between a low of ₹229.95 and a high of ₹328.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Trident Lifeline Ltd has a market capitalization of approximately 323.74. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Trident Lifeline Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.00 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 323.74 Cr, Trident Lifeline Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Trident Lifeline Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Trident Lifeline Ltd is 17.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
68.80 | 363 Cr | 37.15 | 1.12 | 0.00 | 22.69 | 25.33 | 9.70 | ||
39.67 | 337 Cr | 29.04 | 5.04 | 0.00 | 16.97 | 20.65 | 8.44 | ||
212.95 | 334 Cr | 35.71 | 3.05 | 0.00 | 8.14 | 13.29 | 5.02 | ||
249.95 | 324 Cr | 17.00 | 3.22 | 0.00 | 18.97 | 18.05 | 8.16 | ||
137.50 | 315 Cr | 32.57 | 3.45 | 0.00 | 11.59 | 11.00 | 6.01 | ||
236.60 | 307 Cr | -12.63 | 11.63 | 0.00 | -417.29 | -15.11 | -17.94 | ||
405.00 | 295 Cr | 63.91 | 14.77 | 0.00 | 19.79 | 23.50 | 10.61 | ||
| Median: 7 Co. | — | 212.95 | 324 Cr | 32.57 | 3.45 | 0.00 | 16.97 | 18.05 | 8.16 |
Audited results & appointment
Board approved and submitted audited standalone and consolidated financial results for the half-year and year ended 31 Mar 2026, and appointed DAC & Co. (FRN:137035W, PR:014160) as Internal Auditor for FY2026–27.
Audited Results & Appointment
Board meeting on 07 May 2026 approved and filed audited standalone and consolidated financial results for the half year and year ended 31 Mar 2026 with an unmodified audit opinion, and appointed DAC & Co. (FRN:137035W, PR:014160) as Internal Auditor for FY2026-27.
Audited Financial Results
Board approved and took on record audited standalone and consolidated financial results for the half year and year ended 31 Mar 2026 with an unmodified auditor's opinion; DAC & Co. appointed as internal auditor for FY2026‑27.
Audited Financial Results
Board approved and submitted audited standalone and consolidated financial results for the half year and year ended 31-Mar-2026 with an unmodified auditor's report, and appointed DAC & Co. as Internal Auditor for FY2026-27.
Audited Results & Appointment
Board approved audited standalone and consolidated financial results for the half year and year ended 31 Mar 2026 with an unmodified audit opinion; DAC & Co. appointed as Internal Auditor for FY2026-27.
Audited Financial Results
On 07-May-2026 Trident Lifeline Ltd.'s Board approved the audited standalone and consolidated financial results for the half year and year ended 31-Mar-2026 (auditor's report with unmodified opinion) and appointed DAC & Co. as Internal Auditor for FY2026-27.
